Takeda walks away from Omontys

Share this article:

Takeda and Affymax are parting ways. PMLive reports that Takeda is withdrawing its US marketing application for the anemia drug Omontys and that Affymax is not looking to pick the marketing rights up.

The companies had to recall the drug last year after several patient deaths and allergic reactions. Takeda told PMLive that it looked into the reactions and found they could not be attributed to quality or manufacturing issues.

PMLive says Affymax had three employees as of March, and was running a deficit of around $560 million.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters